Filing Flows › Akebia Therapeutics (AKBA) › Q2 2026
Akebia Therapeutics (AKBA) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
Akebia Therapeutics (AKBA) reported revenue of $49.1M for the second quarter 2026 (Q2 2026), -21% from a year earlier and -8% from the quarter before. Operating margin was -12.9%, net loss $8.9M (18.1% of revenue).
Akebia Therapeutics, Q2 2026: revenue $49.1M (-21% year over year), operating margin -12.9%, net loss $8.9M, operating cash flow $3.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $49.1M | -8% | -21% |
| Operating profit | −$6.3M | — | -145% |
| Net earnings | −$8.9M | — | -3706% |
| Operating cash flow | $3.5M | — | -84% |
| Free cash flow | $2.4M | — | -89% |
What changed
Revenue was $49.1M in Q2 2026, down 21% year over year and down 8% from the previous quarter. Auryxia was the largest line at 52% of revenue. Auryxia lost $21.7M year over year (down 46%), 163% of the total change.
Operating costs exceeded revenue by $6.3M, an operating margin of -12.9%. Total costs grew 15% against a revenue fall of 21%. The fastest-growing cost line was Other operating costs (+212%). The quarter ended with a net loss of $8.9M, narrower than the previous quarter's $9.1M loss.
Operating cash flow was $3.5M (down 84% year over year). Non-cash charges added back $585K of depreciation and $3.2M of share-based compensation. Working capital and other items added $8.6M. Capital expenditures of $1.1M left free cash flow of $2.4M.
Questions
What was Akebia Therapeutics' revenue in the second quarter 2026?
Akebia Therapeutics (AKBA) reported revenue of $49.1M for the second quarter 2026 (Q2 2026), -21% from a year earlier and -8% from the quarter before.
Was Akebia Therapeutics profitable in the second quarter 2026?
Operating loss was $6.3M (-12.9% of revenue) and net loss $8.9M.